Repare Therapeutics Inc.
RPTX
$1.36
$0.118.80%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | -- | 1.07M | 52.40M | 13.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | -- | 1.07M | 52.40M | 13.05M |
| Cost of Revenue | -78.07M | 28.40M | 30.08M | 32.97M | -85.09M |
| Gross Profit | 78.07M | -28.40M | -29.00M | 19.43M | 98.14M |
| SG&A Expenses | 8.84M | 6.44M | 8.32M | 8.62M | 11.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.80M | 34.85M | 38.39M | 41.59M | 43.91M |
| Operating Income | -30.80M | -34.85M | -37.32M | 10.82M | -30.87M |
| Income Before Tax | -28.67M | -33.92M | -34.45M | 13.79M | -27.84M |
| Income Tax Expenses | 0.00 | 485.00K | 326.00K | 629.00K | 190.00K |
| Earnings from Continuing Operations | -28.67M | -34.41M | -34.77M | 13.16M | -28.03M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.67M | -34.41M | -34.77M | 13.16M | -28.03M |
| EBIT | -30.80M | -34.85M | -37.32M | 10.82M | -30.87M |
| EBITDA | -30.34M | -34.37M | -36.83M | 11.32M | -30.36M |
| EPS Basic | -0.67 | -0.81 | -0.82 | 0.31 | -0.67 |
| Normalized Basic EPS | -0.42 | -0.48 | -0.51 | 0.20 | -0.41 |
| EPS Diluted | -0.67 | -0.81 | -0.82 | 0.30 | -0.67 |
| Normalized Diluted EPS | -0.42 | -0.48 | -0.51 | 0.20 | -0.41 |
| Average Basic Shares Outstanding | 42.51M | 42.45M | 42.45M | 42.23M | 42.14M |
| Average Diluted Shares Outstanding | 42.51M | 42.45M | 42.45M | 44.02M | 42.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |